Table 3. Determinants of LT4 dose (increase per unit µg/kg/d), n = 556.

Determinant	β	[95% CI]	p
Age 40–49 years (vs. 30–39 years)	0.06	[−0.09; 0.22]	0.437
Age 50–59 years (vs. 30–39 years)	0.06	[−0.09; 0.21]	0.433
Age 60–69 years (vs. 30–39 years)	−0.09	[−0.25; 0.07]	0.267
Age ≥ 70 years (vs. 30–39 years)	−0.09	[−0.26; 0.08]	0.297
Sex (men vs. women)	−0.02	[−0.13; 0.10]	0.783
Education (low vs. middle)	−0.04	[−0.30; 0.22]	0.744
Education (high vs. middle)	−0.00	[−0.09; 0.08]	0.941
Smoking (former vs. never)	0.05	[−0.04; 0.13]	0.285
Smoking (current vs. never)	0.11	[−0.02; 0.24]	0.106
Diabetes (yes vs. no)	0.07	[−0.11; 0.26]	0.431
Hypertension (yes vs. no)	−0.06	[−0.15; 0.03]	0.209
CVD (yes vs. no)	0.03	[−0.12; 0.17]	0.720
CKD (yes vs. no)	0.08	[−0.10; 0.27]	0.371
Iodine supplementation (yes vs. no)	−0.19	[−0.28; −0.10]	<0.001
Polypharmacy (yes vs. no)	0.03	[−0.06; 0.13]	0.493
TSH (mU/L, increase per unit)	−0.00	[−0.03; 0.02]	0.704
LT4 intake duration 13–36 months (vs. 0–12 months)	0.02	[−0.17; 0.21]	0.838
LT4 intake duration > 36 months (vs. 0–12 months)	0.24	[0.07; 0.41]	0.006

The sample size is based on individuals with complete data on all determinants.

BMI, Body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease;

LT4, levothyroxine; n, number of participants; TSH, thyrotropin; vs., versus